{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:34:13Z","timestamp":1786980853463,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After breast cancer treatment, follow-up consists of physical examination and mammography for at least 5 years, to detect local and regional recurrence. The risk of recurrence may decrease after event-free time. This study aims to determine the risk of local recurrence (LR) as a first event until 5 years after diagnosis, conditional on being event-free for 1, 2, 3 and 4 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From the Netherlands Cancer Registry, all M0 breast cancers diagnosed between 2005 and 2008 were included. LR risk was calculated with Kaplan\u2013Meier analysis, overall and for different subtypes. Conditional LR (assuming\n                      <jats:italic>x<\/jats:italic>\n                      event-free years) was determined by selecting event-free patients at\n                      <jats:italic>x<\/jats:italic>\n                      years, and calculating their LR risk within 5 years after diagnosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five-year follow-up was available for 34,453 patients. Overall, five-year LR as a first event occurred in 3.0%. This risk varied for different subtypes and was highest for triple negative (6.8%) and lowest for ER+PR+Her2\u2212 (2.2%) tumors. After 1, 2, 3 and 4 event-free years, the average risk of LR before 5 years after diagnosis decreased from 3.0 to 2.4, 1.6, 1.0, and 0.6%. The risk decreased in all subtypes, the effect was most pronounced in subtypes with the highest baseline risk (ER\u2212Her2+ and triple negative breast cancer). After three event-free years, LR risk in the next 2 years was 1% or less in all subtypes except triple negative (1.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The risk of 5-year LR as a first event was low and decreased with the number of event-free years. After three event-free years, the overall risk was 1%. This is reassuring to patients and also suggests that follow-up beyond 3 years may produce low yield of LR, both for individual patients and studies using LR as primary outcome. This can be used as a starting point to tailor follow-up to individual needs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-020-06040-3","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T01:03:09Z","timestamp":1615338189000},"page":"863-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Conditional local recurrence risk: the effect of event-free years in different subtypes of breast cancer"],"prefix":"10.1007","volume":"186","author":[{"given":"M.","family":"Moossdorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-5329","authenticated-orcid":false,"given":"Marissa L. G.","family":"Vane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J. A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"van Maaren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Goorts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Heuts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. J. A.","family":"Strobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"6040_CR1","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/ijc.27895","volume":"132","author":"C Allemani","year":"2013","unstructured":"Allemani C, Minicozzi P, Berrino F et al (2013) Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000\u20132002. Int J Cancer 132:2404\u20132412","journal-title":"Int J Cancer"},{"key":"6040_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1177\/000313481408000626","volume":"80","author":"AK Arrington","year":"2014","unstructured":"Arrington AK, Goldstein L, Kruper L, Vito C, Yim J, Chen SL (2014) Life expectancy after curative-intent treatment of breast cancer: impact on long-term follow-up care. Am Surg 80:604\u2013609","journal-title":"Am Surg"},{"key":"6040_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdt424","volume":"25","author":"ML Janssen-Heijnen","year":"2014","unstructured":"Janssen-Heijnen ML, van Steenbergen LN, Voogd AC et al (2014) Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Ann Oncol 25:64\u201368","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"6040_CR4","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S et al (2015) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v8-30","journal-title":"Ann Oncol"},{"key":"6040_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.2015.64.3809","volume":"34","author":"CD Runowicz","year":"2016","unstructured":"Runowicz CD, Leach CR, Henry NL et al (2016) American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol 34:611\u2013635","journal-title":"J Clin Oncol"},{"key":"6040_CR6","unstructured":"NABON, Vereniging van Integrale Kankercentra (2012) Breast Cancer: Nation-wide guideline (2.0), pp 1\u2013297"},{"key":"6040_CR7","unstructured":"NICE (2009). Early and locally advanced breast cancer: diagnosis and treatment. Full guideline. Velindre NHS Trust, Cardiff, Wales"},{"key":"6040_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1186\/1471-2407-12-460","volume":"12","author":"XQ Yu","year":"2012","unstructured":"Yu XQ, Baade PD, O\u2019Connell DL (2012) Conditional survival of cancer patients: an Australian perspective. BMC Cancer 12:460","journal-title":"BMC Cancer"},{"key":"6040_CR9","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1200\/JCO.2009.23.0573","volume":"28","author":"BA Zamboni","year":"2010","unstructured":"Zamboni BA, Yothers G, Choi M et al (2010) Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07. J Clin Oncol 28:2544\u20132548","journal-title":"J Clin Oncol"},{"key":"6040_CR10","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1200\/JCO.2009.25.9697","volume":"28","author":"ML Janssen-Heijnen","year":"2010","unstructured":"Janssen-Heijnen ML, Gondos A, Bray F et al (2010) Clinical relevance of conditional survival of cancer patients in Europe: age-specific analyses of 13 cancers. J Clin Oncol 28:2520\u20132528","journal-title":"J Clin Oncol"},{"key":"6040_CR11","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2014.55.1713","volume":"32","author":"ML Kurta","year":"2014","unstructured":"Kurta ML, Edwards RP, Moysich KB et al (2014) Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol 32:4102\u20134112","journal-title":"J Clin Oncol"},{"key":"6040_CR12","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.2012.46.1574","volume":"31","author":"O Metzger-Filho","year":"2013","unstructured":"Metzger-Filho O, Sun Z, Viale G et al (2013) Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol 31:3083\u20133090","journal-title":"J Clin Oncol"},{"key":"6040_CR13","unstructured":"World Health Organization (2000) International classification of diseases for oncology, 3rd edn. http:\/\/codes.iarc.fr\/codegroup\/1. Accessed 16 May 2017"},{"key":"6040_CR14","unstructured":"AJCC AJCOC (2000) AJCC 6th Ed Cancer Staging Manual. https:\/\/cancerstaging.orgreferences-toolsdeskreferencesPagesdefault.aspx. https:\/\/cancerstaging.org\/references-tools\/deskreferences\/Pages\/default.aspx. Accessed 16 May 2017."},{"key":"6040_CR15","unstructured":"CBO Kwaliteitsinstituut voor de Gezondheidszorg, Vereniging van Integrale Kankercentra (2005) Guideline 'Treatment of breast cancer' (Richtlijn 'Behandeling van het Mammacarcinoom'). 2005. http:\/\/www.oncoline.nl\/uploaded\/FILES\/mammacarcinoom\/Richtlijn%20Behandeling%20van%20het%20Mammacarcinoom%20oktober%202005.pdf."},{"key":"6040_CR16","doi-asserted-by":"publisher","first-page":"dju288","DOI":"10.1093\/jnci\/dju288","volume":"106","author":"M Moossdorff","year":"2014","unstructured":"Moossdorff M, van Roozendaal LM, Strobbe LJ et al (2014) Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 106:dju288","journal-title":"J Natl Cancer Inst"},{"key":"6040_CR17","doi-asserted-by":"publisher","first-page":"e5746","DOI":"10.1097\/MD.0000000000005746","volume":"96","author":"H-J Paik","year":"2017","unstructured":"Paik H-J, Lee SK, Ryu JM et al (2017) Conditional disease-free survival among patients with breast cancer. Medicine (Baltimore) 96:e5746","journal-title":"Medicine (Baltimore)"},{"key":"6040_CR18","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrclinonc.2013.124","volume":"10","author":"M Ignatiadis","year":"2013","unstructured":"Ignatiadis M, Sotiriou C (2013) Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol 10:494\u2013506","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"6040_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/ijc.31914","volume":"144","author":"MC van Maaren","year":"2019","unstructured":"van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML et al (2019) Ten-year recurrence rates for breast cancer subtypes in the Netherlands: a large population-based study. Int J Cancer 144(2):263\u2013272","journal-title":"Int J Cancer"},{"key":"6040_CR20","unstructured":"NCCN (2017) National Comprehensive Cancer Network\u2014NCCN Guidelines Breast Cancer Version 2.2017. Published online April 26. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_blocks.pdf. Accessed 19 May 2017"},{"key":"6040_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-015-3490-4","volume":"152","author":"A Witteveen","year":"2015","unstructured":"Witteveen A, Vliegen IMH, Sonke GS, Klaase JM, Ijzerman MJ, Siesling S (2015) Personalisation of breast cancer follow-up: a time-dependent prognostic nomogram for the estimation of annual risk of locoregional recurrence in early breast cancer patients. Breast Cancer Res Treat 152:627\u2013636","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06040-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-020-06040-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-06040-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T20:07:29Z","timestamp":1617480449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-020-06040-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["6040"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-06040-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M.L. Smidt, has been awarded a grant from Servier Pharma for microbiome research in breast cancer treatment. The remaining authors have no disclosures or conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Due to its retrospective design, ethical approval was not obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}